Abstract
Azathioprine therapy is discontinued in one-third of patients with inflammatory bowel disease because of toxicity or a lack of clinical response. Patients with thiopurine methyltransferase (TPMT) deficiency are intolerant to azathioprine, whilst carriers are at increased risk of side-effects.
Lingua originale | English |
---|---|
pagine (da-a) | 1743-1750 |
Numero di pagine | 8 |
Rivista | ALIMENTARY PHARMACOLOGY & THERAPEUTICS |
Volume | 16 |
Stato di pubblicazione | Pubblicato - 2002 |
Pubblicato esternamente | Sì |
Keywords
- Adult
- Azathioprine
- Biological Markers
- Erythrocytes
- Female
- Genotype
- Humans
- Immunosuppressive Agents
- Inflammatory Bowel Diseases
- Leukocyte Count
- Logistic Models
- Male
- Methyltransferases
- Middle Aged
- Odds Ratio
- Retrospective Studies
- Treatment Failure